scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson's disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups

Mental Health Phase IV Completed August 07, 2008 July 02, 2010

Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly

Central Nervous System Phase II Completed June 11, 2008 October 14, 2008

EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)

Allergy Phase III Completed May 22, 2008 August 27, 2008

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides

Blood Disorders Phase II Completed April 28, 2008 September 02, 2008

A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis

Central Nervous System Phase II Completed April 13, 2008 April 19, 2010

Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, multicentre, randomised, double-blind, placebo-controlled study.

Central Nervous System Phase II Completed March 20, 2008 November 03, 2008

Efficacy and tolerability of 12-weeks oral treatment with V0355CP3A versus Ferrograd, in iron deficiency anaemia. Multicenter, randomised, open-label trial

Blood Disorders Phase III Completed February 29, 2008 March 31, 2009

Study of the analgesic effects of repeated doses of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain. A multinational, multicenter, randomized, double blind, parallel groups, placebo-controlled study.

Central Nervous System Phase II Completed February 19, 2008 December 03, 2008

Efficacy and safety study of the antihistamine V0114CP 2.5MG in the treatment of perennial allergic rhinitis. Randomised, double blind, tree arm parallel group study including placebo and active control

Allergy Phase III Completed February 13, 2008 August 27, 2009

Efficacy study of Ciclopiroxolamine 1% foam (DC115 GM 02A) versus Ciclopiroxolamine 1.5% shampoo (SEBIPROX®) in the treatment of moderate seborrheic dermatitis of the scalp

Dermatology Phase II Completed 2008 December 14, 2009

Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects

Dermatology Phase II Completed 2008 April 16, 2009

Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control

Allergy Phase III Early termination 2008 May 19, 2009

Etude randomisée, en groupes parallèles, en double insu, de l'efficacité de la méquitazine sur la symptomatologie et l'obstruction nasale chez des patients présentant une rhinite allergique perannuelle

Allergy Phase IV Completed December 06, 2007 February 24, 2009

Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life." A randomized, double-blind, placebo-control, parallel-group study on 150 patients

Hormonal Phase III Early termination December 03, 2007 May 01, 2008

Evaluation of erectyle disfonction in patients suffering from testosterone deficiency, before and after tretament by Testopatch

Hormonal Phase IV Early termination October 16, 2007 May 02, 2018

Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups

Mental Health Phase II Completed October 16, 2007 December 16, 2009

Non inferiority study of Metronidazole 0.75% cream versus reference therapy in the local treatment of papulopustular rosacea

Dermatology Phase III Completed July 25, 2007 May 13, 2008

Evaluation Of The Rate Of Pathological Complete Response (pCR) For Neoadjuvant Chemoradiotherapy (CT-RT) And For Chemotherapy (CT) Alone in Locally Advanced Non Small Cell Lung Cancer (LA-NSCLC): A Randomized Phase II trial

Oncology Phase II Completed June 26, 2007 December 05, 2007

A Phase II double-blind vehicle controlled crossover single dose (400 µG) V0147 gel effect and tolerance study in spinal cord injured patients with erectile dysfunction

Reproductive Phase II Completed June 04, 2007 July 25, 2007

Etude en double aveugle versus placebo de l'efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses

Cardiovascular Phase IV Completed June 01, 2007 December 13, 2007

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA